NEW MEMBER SIGN UP
  Display Name
 
  Email Address
 
  Password
 
  Password again
 
  Zip
 
Country
 
   

Close Window

Privacy Statement
BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
     
Community Login

What is this?
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel Employers
 Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

BIOTECH WORK PORTAL
Career Definitions
Labor Market Reports
Education & Training
Regions

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

ImClone Systems Corporation 

180 Varick Street

New York  New York  10014  U.S.A.
Phone: 212-645-1405 Fax: 212-645-2054


SEARCH JOBS

View Clinical Trials from BioPharm Insight

ImClone Systems Incorporated (Nasdaq: IMCL) is a biopharmaceutical company dedicated to developing breakthrough biologic medicines in the area of oncology. The Company has utilized the many advances made in the fields of molecular biology, oncology, genomics and antibody engineering to build a novel pipeline of product candidates designed to address specific genetic mechanisms involved in cancer growth and development.

ImClone Systems’ goal is to become a fully-integrated biopharmaceutical company that has the capability and resources to take its novel pipeline compounds and develop them from the research and development stage through to commercial manufacture, marketing and sales.

Last Updated: 08-10-04


 Key Statistics


Email:
Ownership:
Web Site: ImClone Systems Corporation
Employees: 221
Symbol: IMCL
 





Collaborations

Bristol-Myers Squibb Company  Princeton, NJ

UCB Pharma  Brussels, Belgium

Merck KGaA  Darmstadt, Germany





 Company News
DxS Ltd Enters Into Collaboration With Bristol-Myers Squibb Company (BMY) And ImClone Systems Incorporated (IMCL) To Provide a K-RAS Companion Diagnostic For ERBITUX(R) 9/2/2009 2:02:23 PM    More...
Eli Lilly and Company (LLY) and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs; ImClone Systems Incorporated (IMCL) to Locate Research HQ in New York City; Company Bringing 125 Scientists With Plans to Expand 7/23/2009 10:00:07 AM    More...
ImClone Systems Incorporated (IMCL) (JOBS) and Bristol-Myers Squibb Company (BMY) Announce Revisions to ERBITUX® (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer 7/20/2009 7:37:55 AM    More...
Level 3 Expands Relationship with ImClone Systems Incorporated (IMCL) 6/29/2009 9:41:56 AM    More...
ImClone Systems Incorporated (IMCL) And Bristol-Myers Squibb Company (BMY) Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S. 3/2/2009 11:27:18 AM    More...
Adding ImClone Systems Incorporated (IMCL)'s Erbitux To Colon Cancer Drug Mix Not Helpful, Radboud University Nijmegen Medical Center Study 2/5/2009 7:14:35 AM    More...
Eli Lilly and Company (LLY) Profit Falls on ImClone Systems Incorporated (IMCL) Charges 1/29/2009 6:24:40 AM    More...
ImClone Systems Incorporated (IMCL) and Bristol-Myers Squibb Company (BMY) Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX(R) 1/26/2009 10:21:57 AM    More...
ImClone Systems Incorporated (IMCL), Bristol-Myers Squibb Company (BMY) Withdraw FDA Application 1/23/2009 3:40:01 PM    More...
Eli Lilly and Company (LLY) Files Form 8-K/A Detailing Pro Forma Impact of ImClone Systems Incorporated (IMCL) Acquisition 1/13/2009 8:37:10 AM    More...
12345678910...